Ionis Pharmaceuticals (IONS - Free Report) reported $119 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 9.2%. EPS of -$0.98 for the same period compares to -$0.87 a year ago.
The reported revenue represents a surprise of -9.51% over the Zacks Consensus Estimate of $131.51 million. With the consensus EPS estimate being -$1.10, the EPS surprise was +10.91%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Commercial Revenue- Spinraza royalties: $38 million versus $48.65 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -24% change.
- Revenue- Commercial Revenue- Tegsedi and Waylivra revenue, net: $9 million compared to the $6.93 million average estimate based on five analysts.
- Revenue- Total commercial revenue: $59 million versus the five-analyst average estimate of $64.61 million. The reported number represents a year-over-year change of -13.2%.
- Revenue- Research and development revenue under collaborative agreements: $60 million versus the five-analyst average estimate of $47.95 million. The reported number represents a year-over-year change of -4.8%.
- Revenue- Commercial Revenue- Licensing and royalty revenue: $11 million versus $7.31 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
- Revenue- R&D Revenue- Collaborative agreement revenue: $49 million versus $40.89 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +25.6% change.
- Revenue- R&D Revenue- WAINUA joint development revenue: $11 million versus the three-analyst average estimate of $23.04 million.
View all Key Company Metrics for Ionis Pharmaceuticals here>>>Shares of Ionis Pharmaceuticals have returned +0.1% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Where Will Stocks Go…
If Biden Wins? If Trump Wins?
The answers may surprise you.
Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!
Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…
1. Medical manufacturer has gained +11,000% in the last 15 years.
2. Rental company is absolutely crushing its sector.
3. Energy powerhouse plans to grow its already large dividend by 25%.
4. Aerospace and defense standout just landed a potentially $80 billion contract.
5. Giant Chipmaker is building huge plants in the U.S.
Hurry, Download Special Report FREE >>
Ionis Pharmaceuticals (IONS - Free Report) reported $119 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 9.2%. EPS of -$0.98 for the same period compares to -$0.87 a year ago.
The reported revenue represents a surprise of -9.51% over the Zacks Consensus Estimate of $131.51 million. With the consensus EPS estimate being -$1.10, the EPS surprise was +10.91%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Commercial Revenue- Spinraza royalties: $38 million versus $48.65 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -24% change.
- Revenue- Commercial Revenue- Tegsedi and Waylivra revenue, net: $9 million compared to the $6.93 million average estimate based on five analysts.
- Revenue- Total commercial revenue: $59 million versus the five-analyst average estimate of $64.61 million. The reported number represents a year-over-year change of -13.2%.
- Revenue- Research and development revenue under collaborative agreements: $60 million versus the five-analyst average estimate of $47.95 million. The reported number represents a year-over-year change of -4.8%.
- Revenue- Commercial Revenue- Licensing and royalty revenue: $11 million versus $7.31 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
- Revenue- R&D Revenue- Collaborative agreement revenue: $49 million versus $40.89 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +25.6% change.
- Revenue- R&D Revenue- WAINUA joint development revenue: $11 million versus the three-analyst average estimate of $23.04 million.
View all Key Company Metrics for Ionis Pharmaceuticals here>>>Shares of Ionis Pharmaceuticals have returned +0.1% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Where Will Stocks Go…
If Biden Wins? If Trump Wins?
The answers may surprise you.
Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!
Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…
1. Medical manufacturer has gained +11,000% in the last 15 years.
2. Rental company is absolutely crushing its sector.
3. Energy powerhouse plans to grow its already large dividend by 25%.
4. Aerospace and defense standout just landed a potentially $80 billion contract.
5. Giant Chipmaker is building huge plants in the U.S.
Hurry, Download Special Report FREE >>
Get the latest research report on IONS - FREE